Early-Stage Repurposing

A common first step in repurposing is to screen libraries of already approved compounds — such as the NCATS Pharmaceutical Collection — against a disease-specific biological assay (i.e., one that tests for cell-killing). From such screens, researchers can select a subset of bioactive compounds for further interrogation in secondary and tertiary assays evaluating relevant aspects of disease biology and molecular pathophysiology.

 NCATS offers various resources to support repurposing efforts across both common and rare diseases. Additionally, the Center’s scientists conduct research in high-throughput assay development and screening, informatics and modeling, and analytical and medicinal chemistry to improve the repurposing process.